Akebia Therapeutics, Inc.
AKBANASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 26, 2026 close
- Market cap
- $173.57M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.61$3.20
- Volume (live)
- -
- Avg. volume (3M)
- 8.09M
Akebia Therapeutics (AKBA) Stock Price & Financial Analysis
Akebia Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $0.58 - $0.68 |
|---|---|
| 52-Week High | $3.20 |
| 52-Week Low | $0.61 |
| Open | $0.59 |
| Volume (last close) | 11.59M |
| Average Volume (3M) | 8.09M |
| Revenue (TTM) | 219.06M |
|---|---|
| Net Income (TTM) | -29.67M |
| Free Cash Flow (TTM) | 40.17M |
| EPS (TTM) | −$0.11 |
| Profit Margin | -13.54% |
| Operating Margin | -6.02% |
| Return on Equity (ROE) | -118.58% |
| Debt to Equity | 1.98 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 173.57M |
|---|---|
| Shares Outstanding | 269.60M |
| Price to Sales (P/S) | 0.79 |
| Price to Book (P/B) | 6.94 |
| EV/EBITDA | -2.99 |
| 50-Day MA | $0.88 |
|---|---|
| 200-Day MA | $1.18 |
| 1-Year Change | −81.13% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Akebia Therapeutics at a Glance
As of the Oct 26, 2026 close, Akebia Therapeutics (AKBA) has a market capitalization of $173.57M. The stock trades at 0.8× sales. Over the trailing twelve months it lost $29.67M on revenue of $219.06M and generated $40.17M of free cash flow. Revenue grew 7.5% year over year.
As of its latest reported balance sheet, it holds $155.55M in cash and securities against $49.56M of debt, a net cash position of $105.98M.
Akebia Therapeutics does not currently pay a dividend.
The share price is down 81.1% over the past year. At $0.64 (the Oct 26, 2026 close) it sits near the bottom of its 52-week range of $0.61 to $3.20, below its 200-day moving average of $1.18.
Based on 5 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $3.90, 505.8% above the Oct 26, 2026 close.
Frequently Asked Questions About Akebia Therapeutics
What is the current stock price for AKBA?
As of the Oct 26, 2026 close, AKBA stock trades at $0.64. The 52-week range is $0.61–$3.20, with a day range of $0.58–$0.68.
What is the P/E ratio for AKBA?
The P/E ratio (Price-to-Earnings) for AKBA is shown in the Key Statistics section. This valuation metric helps compare Akebia Therapeutics, Inc. to industry peers.
Does AKBA pay dividends?
Akebia Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for AKBA?
Based on ratings from 5 professional analysts over the last 90 days, the consensus for AKBA is Buy. The average 12-month price target is $3.90, a 505.8% upside from the Oct 26, 2026 close of $0.64.
What is the market cap of AKBA?
As of the Oct 26, 2026 close, Akebia Therapeutics's market capitalization is $173.6M, classifying it as a micro-cap company. Akebia Therapeutics operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.